Showing 1 - 10 of 165
Background: Candidaemia and other forms of invasive candidiasis (C/IC) are serious and costly events for hospitalized patients, particularly those in the ICU. Both fluconazole and the echinocandins are recommended as first-line therapy for C/IC. Resource use and cost considerations are important...
Persistent link: https://www.econbiz.de/10010614308
Objective: To evaluate the cost effectiveness of a new product, oral ganciclovir, in comparison to a current therapy, intravenous (IV) ganciclovir, in the maintenance treatment of newly diagnosed cytomegalovirus (CMV) retinitis in patients with AIDS. Design: This was a retrospective economic...
Persistent link: https://www.econbiz.de/10005404773
Persistent link: https://www.econbiz.de/10001522456
Persistent link: https://www.econbiz.de/10000666118
Verlagsinfo: Over seven years in preparation, this is the first book-length report to emerge from the Correlates of War project. That project, supported by the Carnegie Corporation and the National Science Foundation, proceeds from the assumption that war - like other natural and man-made...
Persistent link: https://www.econbiz.de/10000032778
Persistent link: https://www.econbiz.de/10002824355
Persistent link: https://www.econbiz.de/10002678769
Persistent link: https://www.econbiz.de/10013536617
Persistent link: https://www.econbiz.de/10014418275
Ambrisentan is less costly than other available ERAs, including bosentan and sitaxentan, but is more costly than sildenafil. In PAH patients in whom an ERA is the preferred agent, ambrisentan may be the drug of choice because of its economic advantages and improved safety profile. </AbstractSection> Copyright...
Persistent link: https://www.econbiz.de/10011000865